← GLP-1 receptor agonists × body weight & composition

TrialEuropean heart journal2024

Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.

Sanjiv J Shah et al.PubMed ↗Full text ↗Publisher ↗

A secondary analysis of NCT04788511. The trial’s primary report, PMID 37622681, speaks for it on the map; the numbers here are shown and do not vote.

  • Semaglutidelooks good hereLower body weight.Weak evidence: one subgroup, may be chance.

What the trial testedrandomised · 1,145 people · 2024

One subgroup · may be chance

May have lowered body weight in no diuretics

Doesn’t vote: a later paper about the trial

−8.80percentage points−10.3 to −6.30

semaglutide vs placebo, in no diuretics

As reported

difference −8.8 %, 95% CI −10.3 to −6.30 · the paper's word: change in body weight

One subgroup · may be chance

May have lowered body weight in highest loop diuretic dose category

Doesn’t vote: a later paper about the trial

−6.90percentage points−9.10 to −4.70

semaglutide vs placebo, in highest loop diuretic dose category

As reported

difference −6.9 %, 95% CI −9.10 to −4.70 · the paper's word: change in body weight

Who was studied, and how

1,145people with heart failure, in this paper

Among no diuretics, the trial randomly assignedassigned by chance

semaglutide
placebo

May have lowered body weight−8.80

randomised · one subgroup, may be chance

Among highest loop diuretic dose category, the trial randomly assignedassigned by chance

semaglutide
placebo

May have lowered body weight−6.90

randomised · one subgroup, may be chance

the abstract, start to end

… mean difference vs. placebo ranged from -8.8% [95% confidence interval (CI) -10.3, -6.3] to -6.9% [95% CI -9.1, -4.7] from no …

← favours treatmentfavours comparator →
could be chance
Change in body weightsemaglutide vs placebo, in no diuretics
−8.8−10.3 to −6.30
Change in body weightsemaglutide vs placebo, in highest loop diuretic dose category
−6.9−9.10 to −4.70
GLP-1 receptor agonistsBody weight & composition
1 / 4

36 papers cite it

2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 38739118